Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Y. Olyunin"'
Publikováno v:
Научно-практическая ревматология, Vol 42, Iss 4, Pp 80-84 (2004)
Objective. To assess efficacy and safety of intramuscular (im) and paravertebral (pv) alflutop injections in pts with chronic vertebrogenous lumbar ischialgia. Material and methods. 83 pts with lumbar ischialgia syndrome (44 male, 39 female) aged 31
Externí odkaz:
https://doaj.org/article/9072831f923d4fb0b1ebd6f6cbd4408d
Publikováno v:
Annals of the Rheumatic Diseases. 81:1239.1-1239
ObjectivesTo compare the features of the disease course and the therapy in rheumatoid arthritis (RA) patients who meet and do not meet the difficult to treat (D2T) criteria.MethodsRA patients admitted to the V.A. Nasonova Research Institute of Rheuma
Publikováno v:
Annals of the Rheumatic Diseases. 81:1218.2-1218
BackgroundPatients (pts) with Difficult-to-Treat Rheumatoid Arthritis (D2T) (EULAR 2021 criteria) are distinguished by a history of failure of two or more biological disease modifying antirheumatic drugs (bDMARDs)/targeted synthetic DMARDs (tsDMARD)
POS1455-HPR RELATIONSHIP BETWEEN PSYCHOLOGICAL FACTORS AND MEASURES OF RHEUMATOID ARTHRITIS ACTIVITY
Publikováno v:
Annals of the Rheumatic Diseases. 80:1011.2-1011
Background:The patient-reported outcomes are important components of quantitative methods of rheumatoid arthritis (RA) activity assessment which are used to choose the appropriate drug therapy. The value of these parameters can be significantly affec
Publikováno v:
Annals of the Rheumatic Diseases. 80:1134.2-1134
Background:Current guidelines for the treatment of rheumatoid arthritis (RA) recommend early administration of methotrexate (MTX) and addition of a biologic if MTX monotherapy does not provide remission or low activity of the disease. Efficacy of thi
Publikováno v:
Annals of the Rheumatic Diseases. 80:1139.1-1139
Background:Disease modifying anti-rheumatic drugs (DMARD) can provide an unbalanced effect on individual components of the inflammatory process, which in some cases leads to an insufficiently correct assessment of the patient’s status when using co
Publikováno v:
Annals of the Rheumatic Diseases. 80:1131.2-1131
Background:Due to the expiration of many originator biologics patents, their biosimilars (BS) have appeared and were put into clinical practice. The introduction of such drugs reduces the cost of treatment and thereby increases its availability. BS r
Autor:
E. L. Luchikhina, M. Kanonirova, N. Demidova, D.E. Karateev, Y. Olyunin, A.A. Novikov, Aleksandrova En, G. Loukina, Nasonov El
Publikováno v:
Annals of the Rheumatic Diseases. 74:976.3-976
Background The Treat to Target (T2T) strategy in rheumatoid arthritis (RA) implies regular review of therapy in order to achieve the optimal outcome - remission or low disease activity (LDA). The majority of patients would require upgrade of therapy
Autor:
Y. Olyunin, Nasonov El, M. Kanonirova, Y. Mouraviev, E. L. Luchikhina, N. Demidova, Galina Lukina, G. Gridneva, D.E. Karateev
Publikováno v:
Annals of the Rheumatic Diseases. 73:235.2-236
Background According to Treat to Target (T2T) recommendations the primary goal of treatment of patients (pts) with rheumatoid arthritis (RA) is clinical remission. This implies a revision of treatment every 3-6 months with the use of combination ther
Autor:
D.E. Karateev, E. L. Luchikhina, N. Demidova, Y. Muravyev, Nasonov El, Galina Lukina, E. Lopareva, Y. Olyunin, G. Gridneva
Publikováno v:
Annals of the Rheumatic Diseases. 72:A893.2-A893
Background Monotherapy with MTX is the first step of RA therapy as recommended by EULAR. In accordance with the principles of T2T insufficient response to MTX requires quick switch to a combination therapy with biological agents. Objectives We compar